Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (5543)	1/24/2002 10:13:04 PM
From: scott_jiminez	Read Replies (2) of 52153

Ariad actually had very little hype. They simply let their many papers speak for the company. And your stuff about the ARIA spike... Let's see now Peter, during the same period: - AFFX: went from 8 to 150 - CRA: went from 7 to 250 - CRGN: went from 2 to 125 - GENE: went from 5 to 80 - GLGC: went from 3 to 150 - HYSQ: went from 4 to 130 and on and on and on…. Hmmmm. Actually what happened with ARIA is that it went along for the ride while all the over-hyped, product-challenged genomics companies did everything they possibly could to 'encourage the feeding frenzy'. Certainly the hype by dozens of genomics BTs was orders-of-magnitude more extreme than ARIA could have even manufactured. Sorry, Peter. ARIA was a follower, not a leader, in the feeding frenzy department. They didn't need the PR.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next